The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim
Richard S. Finn
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Masatoshi Kudo
No relevant relationships to disclose
Josep M. Llovet
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly
Honoraria - Bayer; Bristol-Myers Squibb; Lilly
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb
Shukui Qin
No relevant relationships to disclose
Marie-Aude Le Berre
No relevant relationships to disclose
Heiko Krissel
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Jordi Bruix
Consultant or Advisory Role - AngioDynamics; ArQule; Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Novartis; OSI Pharmaceuticals; Roche; Sanofi
Honoraria - Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb
Research Funding - AngioDynamics; ArQule; Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb; Merck; Novartis; OSI Pharmaceuticals; Roche